Clinical TrialID 5540
Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
NCT04121767
Atrial Fibrillation|Anticoagulants and Bleeding Disorders
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5540
- Evidence Id
- 5540
- Core Evidence Id
- 5540
- Source Clinical Trial Id
- 5522
- Herb2 Clinical Trial Id
- HBCT005522
- Nct Id
- NCT04121767
- Title
- Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
- Status
- Completed
- Phase
- Study Result
- No
- Study Condition
- Atrial Fibrillation|Anticoagulants and Bleeding Disorders
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
- Intervention
- DRUG: Edoxaban|DRUG: Warfarin
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Intervention Purpose
- Prevention
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 60
- Outcome Measure
- Postoperative stroke, Number of patients showing thromboembolic neurologic complication after thoracoscopic ablation, 6 months
- Sponsor Collaborator
- Samsung Medical Center
- Funded By
- OTHER
- Location
- Samsung Medical Center, Seoul, 135-710, Korea, Republic of
- Other Id
- samsungmc_TTA_edoxaban
- Start Date
- 2017-12-01
- Primary Completion Date
- 2020-06-30
- Completion Date
- 2020-07-10
- First Posted
- 2019-10-10
- Results First Posted
- Last Update Posted
- 2020-08-03
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT04121767
- Title Cn
- Title En
- Safety and Efficacy of Edoxaban in Thoracoscopic Ablation
- Bilingual Status
- semi_complete